HeartSciences Inc. (NASDAQ:HSCS) Short Interest Update

HeartSciences Inc. (NASDAQ:HSCS) was the target of a large drop in short interest in August. As of August 14th, there was short interest totaling 50,682 shares, a drop of 33.3% from the July 30th total of 76,030 shares. Currently, 1.4% of the company’s stock are short sold. Based on an average daily volume of 66,843 shares, the days-to-cover ratio is presently 0.8 days.

HeartSciences Stock Performance

Shares of HSCS stock traded down $0.03 during trading hours on Tuesday, reaching $3.12. The company had a trading volume of 63,198 shares, compared to its average volume of 881,764. The business has a fifty day moving average price of $2.53 and a 200-day moving average price of $2.35. HeartSciences has a one year low of $1.63 and a one year high of $3.80. The firm has a market cap of $12.17 million, a PE ratio of -0.79 and a beta of 1.79.

HeartSciences (NASDAQ:HSCS) last issued its quarterly earnings data on Thursday, July 23rd. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.22). Equities research analysts forecast that HeartSciences will post -3.04 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a research note on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $8.00.

Hedge Funds Weigh In On HeartSciences

A hedge fund recently bought a new stake in HeartSciences stock. Geode Capital Management LLC purchased a new position in HeartSciences Inc. (NASDAQ:HSCS) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned about 0.51% of HeartSciences at the end of the most recent reporting period. Institutional investors and hedge funds own 17.24% of the company’s stock.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non?invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high?fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high?frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.